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1. Introduction  
Colorectal cancer (CRC) is one of the commonest cancers and the third leading cause of 
cancer death. In the developed world more than 1 million individuals will develop 
colorectal cancer every year (Parkin et al. 2005). According to the Surveillance, 
Epidemiology and End Results (SEER) Program database, the prognosis of CRC has an 
improving trend. 5-year survival rates have risen from 56.5% for patients diagnosed in the 
early 1980s to as much as 63.2% for those diagnosed in the early 1990s and most recently to 
64.9%. Currently, rectal cancer is usually discussed together with colon cancer and 
historically accounted for more than 50% of CRCs. However, this has now decreased to less 
than colon cancers; in a recent review the incidence in the European Union was 
approximately 35% of the total CRC incidence (Glimelius and Oliveira 2009). The prognosis 
of rectal cancers is worse than that of colon cancers (Enblad et al. 1988), and the clinical 
treatment of rectal cancers is different from that of colon cancers (Vo et al. 2010). Rectal 
cancer is a very different tumor from colon cancer because of the anatomical narrow 
confines of the pelvis, the proximity of the genitourinary organs and nerves, and the anal 
sphincter mechanism. Oncological cure remains the primary aim of treatment for rectal 
cancer, but sparing of the anal sphincters with adequate bowel, genitourinary, and sexual 
function is also taken into consideration. 
Pre-operative staging is crucial to stratify patients into one of three treatment strategies: 
patients whose tumors are superficial require surgery alone, patients with operable tumors 
but at an increased risk of local recurrence require short course radiotherapy and then 
optimal surgery, and thirdly those with more locally advanced rectal cancers with close or 
involved circumferential resection margins require neoadjuvant chemoradiation (CRT) 
followed by surgery. Early detection and treatment is vital to better survival. The five year 
survival rate of patients diagnosed with early stage CRC is approximately 90% as opposed 
to close to 10% for those diagnosed with locally advanced or metastatic disease. Indeed, the 
median survival of patients with metastatic CRC is only two years despite multiple 
available treatment modalities, including surgical resection, chemoradiation, monoclonal 
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antibodies to tumor growth factors, and liver-directed therapies for metastatic disease. Few 
patients are sensitive to these therapies and even fewer are cured.  
The early pathway to CRC tumorigenesis has been well elucidated by the seminal work of 
Vogelstein and colleagues in which a single colorectal epithelial cell acquires a mutation in the 
tumor suppressor APC gene (Jones et al. 2008). The cells subsequently acquire a complex array 
of molecular mutations and quickly acquire the potential to metastasize (Jones et al. 2008). The 
concept of clonal evolution which postulated that tumor progression results from acquired 
genetic variability within the original mutated clone allowing sequential selection of more 
aggressive sub-lines provided a ready explanation for the relentless advance toward ever more 
malignant behavior within established tumors (Nowell 1976) including colorectal cancer 
(Fearon and Vogelstein 1990). However, prior to the theory of clonal evolution, the cancer stem 
cell concept had been formulated to account for the heterogeneity, resistance to treatment, and 
dormancy exhibited by many solid tumors (Pierce and Speers 1988). The CSC concept 
postulated that, similar to the growth of normal proliferative tissues such as bone marrow, 
skin or intestinal epithelium, the growth of tumors is driven by limited numbers of dedicated 
stem cells that are capable of self-renewal. More recently, the CSC concept has gained more 
momentum due to studies in leukemia. These studies showed that engraftment of tumors in 
an immunodeficient mouse could only be initiated from a specific subpopulation of 
CD34+CD38− cells and led to the identification of a CSC in acute myeloid leukemia (AML) 
(Bonnet and Dick 1997). In 2003, Clarke and colleagues (Al-Hajj et al. 2003) applied the same 
concepts and experimental approaches to a solid breast cancer tumor and showed that as few 
as 100 CD44+CD24−/low cells were tumorigenic, whereas tens of thousands of cells with 
alternate phenotypes were not. CSC theory and clonal evolution are not mutually exclusive, 
and it is likely that a single tumor may contain multiple cancer stem cell clones that are 
genetically distinct. However, they will always have a common ancestor in the stem cell that 
sustained the first oncogenic mutation and became the origin of the tumor. 
2. Cancer stem cell theory 
Stem cell concepts and their application to cancer is not a new subject (Clevers 2011; Wicha 
et al. 2006). As far back as the nineteenth century, it was recognized that tumors exhibit 
profound histological heterogeneity. In the 1930’s, it was discovered that a single cell from a 
mouse tumor could initiate a new tumor in a recipient mouse. Subsequently, several studies 
showed that the number of cells with tumor-initiating properties in solid tumors and 
leukemias was found to be variable but low (103 to 107 cells). The resulting tumors typically 
showed the morphologic heterogeneity of the original tumor. 
CSCs possess several key properties of normal tissue stem cells including self-renewal, 
unlimited proliferative potential, infrequent or slow replication, resistance to toxic 
xenobiotics, enhanced DNA repair capacity, and the ability to give rise to daughter cells that 
differentiate. However, unlike highly regulated tissue stem cells, CSCs demonstrate 
deregulated self-renewal/differentiation processes and generate daughter cells that arrest at 
various stages of differentiation. The progeny of the stem cells make up the bulk of the 
tumor and are characterized by rapid replication, limited proliferative potential, and the 
inability to form a new tumor. Only the CSC is able to initiate tumor formation as it is solely 
capable of self-renewal (Figure 1). CSCs are thought to maintain their numbers by slow self-
replication and produce other tumor cells by asymmetric cell division. In this process, cell 
division of a CSC generates a CSC and a transformed “progenitor-like” cell, which has 
limited self-renewal ability but is highly proliferative, similar to a transit-amplifying  
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Fig. 1. The cancer stem cell hypothesis. In normal tissues, cell numbers are regulated by 
asymmetric division of stem cells to replace the loss of functional differentiated cells. In 
cancer, the mutated stem cell drives tumor heterogeneity through asymmetric division and 
aberrant proliferation/differentiation. Only the CSC has the capacity to form new tumors 
and accumulate further mutations leading to tumor progression. 
population in normal tissues. These progenitors give rise to more or less partially 
differentiated bulk tumor cells through a combination of proliferation and abortive 
differentiation. 
The existence of CSCs has been supported by seminal research performed on acute myeloid 
leukemia (AML), where it has been demonstrated that only a specific cellular subset that 
express antigenic markers similar to hematopoietic stem cells has clonogenic activity in 
immunocompromised mice (Lapidot et al. 1994; Bonnet and Dick 1997). The cell responsible 
for tumor initiation was identified as having a CD34+ CD38− phenotype; interestingly the 
majority of AML cells tend to be CD34−. It was observed that as few as 5 ×103 CD34+ CD38− 
cells could successfully engraft an immunocompromised mouse, while 100 times more 
CD34− or CD34+ CD38+ cells were not tumorigenic (Bonnet and Dick 1997). Significantly, the 
resulting tumors were heterogeneous and composed of a mixture of tumorigenic and non-
tumorigenic cells similar to the donor leukemia. Subsequently, studies on tumors of 
epithelial origin, such as breast cancer, also provided evidence for the presence of stem-like 
cells within the cancer (Dontu et al. 2005). Ponti and colleagues demonstrated that only 
CD44+/CD24- cells, isolated from breast cancer, were able to produce tumors in 
immunocompromised mice (Ponti et al. 2005). The initial publications in leukemia and 
breast cancer were followed by reports showing the prospective isolation of CSCs in 
numerous malignancies including: brain, colon, head and neck, pancreatic, melanoma, 
mesenchymal, hepatic, lung, prostate, and ovarian tumors (O'Brien et al. 2010). The 
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existence of CSCs in rectal cancer has yet to be verified by stem cell isolation and 
xenotransplantation into immunodeficient mice. 
3. Intestinal structure and the stem cell niche 
The large bowel consists of a rapidly proliferating and perpetually differentiating 
epithelium. Unlike the small intestine, the mucosal surface of the colon has no villi. The 
ileocecal junction marks an abrupt transition from the villi of the small intestine to the 
smooth glandular pattern of colon. The crypts of Leiberkuhn continue, and these straight  
tubular glands are lined with simple columnar epithelium for the reabsorbtion of water and 
electrolytes, numerous goblet cells for mucus secretion, stem cells for replication, and 
occasional enteroendocrine cells. Stem cells located in the crypts of Lieberkuhn give rise to 
proliferating progenitor or transit amplifying cells that differentiate into the four major 
epithelial cell types (Figure 2). These include columnar absorptive cells or enterocytes, 
mucous-secreting goblet cells, enteroendocrine cells, and Paneth cells. Enterocytic, goblet, and 
enteroendocrine cell differentiation takes place during migration upward from the crypt to the 
surface epithelium, whereas Paneth cells complete their differentiation at the crypt base. The 
crypt is surrounded by the supporting lamina propria which contains cells of mesenchymal 
origin, the pericryptal myofibroblasts, which are derived from a mesenchymal lineage. 
 
 
Fig. 2. The intestinal stem cell structure. Two putative populations of stem cells exist:  
(1) a quiescent/reserved population that consists of label retaining cells located above the 
basally situated Paneth cell and (2) an actively cycling/primed population that consists of 
crypt base columnar cells. 
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Much of the detailed research on intestinal stem cells has been carried out in the setting of 
the small intestine where the localization of putative intestinal stem cells (ISCs) was initially 
studied using indirect means. Based on the premise that stem cells may be slowly cycling, 
Potten and colleagues used long-term label retaining techniques (tritiated thymidine or 
bromodeoxyuridine) to mark putative ISCs in the small intestine (Potten et al. 1997). They 
detected long-term label-retaining cells (LRCs) in an annulus four cells up (+4 LRCs) from 
the crypt base. More recently, using in vivo lineage tracing, it was shown that cells 
expressing BMI1 predominantly mark +4 LRC position and are able to give rise to all four 
epithelial lineages (Sangiorgi and Capecchi 2009). BMI1 encodes a chromatin remodeling 
protein of the polycomb group that has essential roles in self-renewal of hematopoietic and 
neural stem cells. However, an alternative hypothesis was put forward by Barker and 
colleagues, who identified a WNT target gene, LGR5/GPR49, which is expressed 
exclusively in crypt base columnar cells (CBCs) at crypt positions 1–4 (Barker et al. 2007). 
They elegantly showed that LGR5- expressing CBCs fulfill all criteria of putative ISCs in that 
they can persist for a long time, self-renew, give rise to all mature intestinal epithelial cells, 
and are also apoptosis-resistant. However, in contrast to the putative +4 LRC/BMI1  
cells, they are highly proliferative. This raises the possibility that there are two types of 
intestinal stem cells: quiescent stem cells +4 LRC/BMI1 reflecting their inhibitory 
microenvironment, and the active CBC/LGR5-positive stem cells, representing a population 
of stem cells able to respond to stimulating signals generated from adjacent mesenchymal 
cells (Scoville et al. 2008). Very recently, work from Clevers laboratory has implicated the 
Paneth cell as an important component of the CBC/LGR5 niche (Sato et al. 2011). 
There are clear differences between the small and large intestine, apart from the lack of villi. 
Paneth cells are not generated in the large intestine, and there are differences in the 
enteroendocrine cell types. However, colonic stem cells have also been shown to reside in the 
base of the crypts within the stem-cell niche, which is formed by the stem cells themselves and 
mesenchymal cells that surround the crypt base (Potten 1998). Using bromodeoxyuridine 
injections into patients with various colorectal cancers, we were able to show marked 
differences in the proliferation characteristics of “normal” ileum, colon and rectal mucosa 
(Potten et al. 1992). The mean crypt height in sections of the human colon was 81.9 and 79.5 
cells for the rectum. The mean crypt circumference was 41.6 cells in the colon, and 46.0 cells in 
the rectum. This gave a total of 2044 cells per crypt in the colon and 2194 cells per crypt in the 
rectum. In the colonic crypts 10% of cells were in S phase and 0 4% in mitosis. Ninety per cent 
of labeled cells were found between cell positions 4 and 43; we showed that the maximum 
labeling index was about 30% and occurred at cell position 15. The labeling index at the crypt 
base, the putative stem cell zone, was about 14%. The rectum showed significant differences. 
The rectal mucosal crypts contain approximately 30% fewer S phase and mitotic cells (Figure 
3). This may indicate either that the cell cycle time of rectal mucosa cells is longer than in the 
colon, or that there are fewer proliferating cells in the rectum. Extrapolating from biologic 
studies in rodents suggests that ISCs in the human colonic and rectal crypts represent only a 
small proportion of crypt cells (approximately 20 cells per crypt, or approximately 1%) (Potten 
and Loeffler 1990). This finding is consistent with recent immunostaining studies in human 
colonic crypts for Musashi-1 protein, a putative ISC marker, indicating that there are, on 
average, 19 ISCs per crypt (Potten et al. 2003). 
A key component of tissue architecture that is involved in the regulation of stem cells has 
been termed the “stem cell niche “ (Spradling et al. 2001). The stem cell niche has been well 
characterized in hematopoietic and neural systems and is an intricate and dynamic milieu  
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Fig. 3. A comparison of the bromodeoxyuridine labeling index frequency plots for the 
human colon and the rectum.  
that adapts in response to environmental signals. The niche consists of a stromal 
microenvironment surrounding the stem cell population that can contain neural cells, 
lymphocytes, macrophages, endothelial cells, fibroblasts, smooth muscle cells and 
myofibroblasts in an extracellular matrix (Li and Xie 2005). As mentioned previously, the 
crypt is surrounded by the supporting lamina propria which contains pericryptal 
myofibroblasts. These myofibroblasts are thought to be strategic cells in the regulation of 
stem cell behavior through growth factor and cytokine signaling (Mills and Gordon 2001). 
Several key signaling pathways are common to stem cells and their niche including Wnt, 
BMP and Notch. 
The discovery that mutations in the APC gene, the most important tumor suppressor in 
intestinal tumorigenesis, affects the control of Wnt signaling, indicated the importance of 
this pathway in intestinal stem cell regulation (Korinek et al. 1997). It is thought that the 
pericryptal myofibroblasts produce the Wnt signaling ligands that access Frizzled receptors 
on the basal epithelial stem cells (Fevr et al. 2007), and this prevents degradation of the main 
effector, ǃ-catenin by a destruction complex containing APC and AXIN1/2. ǃ-Catenin 
translocates to the nucleus, where it acts as a transcriptional activator after binding to 
TCF/LEF family members. Korinek et al showed that lack of the intestine specific ǃ-catenin 
partner, TCF4, resulted in the depletion of the epithelial stem cell compartment in the small 
intestine (Korinek et al. 1998). Wnt signaling varies across the crypt (Kosinski et al. 2007) in 
that the crypt top is characterized by APC, WNT5B, and TCF4 whilst the crypt bottom, the 
putative stem cell niche, expresses AXIN2, TCF3, and several secreted Wnt inhibitors 
including DKK3, SFRP1, SFRP2, FZD2, FZD3, FZD7, and FZDB. The identification of many 
different Wnt/ ǃ-catenin target genes indicates that Wnt signaling has different effects in 
different cell types depending on their localization along the crypt axis. The 
microenvironment surrounding the LGR5/GPR49 stem cell is characterized by prominent 
Wnt activity and inhibition of BMP signaling with the presence of BMP inhibitors noggin 
and gremlin whereas the microenvironment surrounding the +4 LRC is characterized by 
expression of the Wnt inhibitor sFRP5 and BMP4 (Pages et al. 2009). 
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This also highlights the importance of members of the BMP pathway as important 
contributors to the colorectal epithelial stem cell niche by modulation of the Wnt pathway. 
Bone morphogenetic proteins (BMPs) bind to BMP receptor types I or II (BMPR1 or BMPR2) 
leading to phosphorylation of SMAD1, 5 or 8, which then form a heterodimer with SMAD4, 
translocate to the nucleus, and act as transcriptional activators (von Bubnoff and Cho 2001). 
Active BMP signaling, indicated by phosphorylated SMADs, is found predominantly in 
differentiated intestinal epithelial cells. Several lines of evidence support the postulated 
inhibitory role of BMP signaling on stem cell self-renewal. These include the observations 
that conditional mutation of BMPR1A resulted in de novo crypt formation and a juvenile 
polyposis phenotype (He et al. 2004) and leads to reduced differentiation into the three 
secretory cells types, Paneth cells, goblet cells and enteroendocrine cells in mice (Auclair et 
al. 2007). Also, human juvenile polyposis has been shown to be associated with mutations in 
the SMAD4/DPC4 or BMPR1A genes (Sayed et al. 2002). 
Several other pathways have been shown to be important in intestinal stem cell regulation 
including Notch signaling, hedgehog signaling, and the PTEN–PI3K–Akt pathway. Notch 
has been implicated in the control of cell fate in many tissues. The binding of the ligands 
Jagged or Delta to the Notch receptor induces proteolytic cleavage by Ǆ–secretase which 
releases a fragment, NCID. This fragment translocates to the nucleus and acts as a 
transcription factor after dimerization with RBP-jκ/CSL. One of the key genes stimulated by 
this activation is a bHLH transcription factor termed hairy/enhancer of split (Hes), which 
has been shown to activate factors involved in the control of proliferation and differentiation 
(Bray 2006). Knocking out RBP-jκ or Hes1 leads to increased numbers of secretory epithelial 
cells (Jensen et al. 2000) whereas mutation in ATOK1, a transcription factor repressed by 
Notch signaling, leads to depletion of all three secretory lineages (Yang et al. 2001). 
Therefore, Notch functions by stimulating proliferation of crypt progenitor cells in the 
transit-amplifying units, and suppression of Notch signaling induces specific differentiation 
into the intestinal epithelial lineages. A role of the PTEN–PI3K–Akt in enhancing stem cell 
self-renewal in the intestine has been suggested as a result of the connection between this 
pathway and the Wnt pathway. p-Akt can phosphorylate ǃ-catenin and thus enhance the 
transcriptional activity of ǃ-catenin whilst PTEN exhibits strongest expression in lumenal 
epithelial cells and might be involved in the restriction of strong Wnt signaling to the crypt 
base (Persad et al. 2001). In contrast to the other signal pathways which seem to be regulated 
in response to ligands originating from the niche cells, the morphogens of the hedgehog 
(HH) pathway, sonic hedgehog (Shh), and Indian hedgehog (Ihh) are secreted by epithelial 
cells. Their receptor, Patched (PTCH), is expressed on the pericryptal myofibroblasts. 
Accordingly, HH signaling is not directly concerned with the fate of the epithelial cells but is 
important in shaping and regulating the proper overall structure of the intestinal mucosa 
into crypts and villi (Madison et al. 2005). 
4. Stem cells and the development of colorectal cancer 
The mechanisms underlying colorectal cancer initiation have yet to be fully elucidated (see 
section 5). It is clear that the APC gene is involved as APC mutations are found in 75% to 
80% of sporadic CRCs (Powell et al. 1992). However, mutations in mitochondrial DNA and 
mutations in the genes encoding cytochrome c oxidase (COX), a component of complex IV 
of the respiratory chain, are also relatively common (Taylor et al. 2003).  
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When an initial mutation occurs in a basally situated crypt stem cell, it gives rise to a clone 
that migrates up the crypt, expanding as it progresses. At this stage the proliferation pattern 
of crypts are shifted toward the crypt top with a maximum labeling index (LI) at 
approximately crypt level 20. The mutant clone then begins to colonize the base of the crypt, 
in effect taking over and replacing the non-mutant cells in the stem-cell niche in a process 
that has been termed niche succession. Eventually the entire niche will be colonized with 
mutant stem cells and the crypt filled with their progeny, a result termed monoclonal 
conversion. Interestingly, crypts containing this proliferative abnormality do not show any 
discernible histological changes. Crypts only begin to show obvious abnormalities when 
they become dysplastic during later formation of premalignant adenomas. Boman and 
colleagues have postulated that only an increase in crypt SC number and not changes in cell 
cycle proliferation, differentiation, or apoptosis of non-SC populations, could explain the LI 
shift in these crypts (Boman et al. 2001). This led to the hypothesis that the link between 
APC mutation and the LI shift is crypt SC overpopulation caused by a decrease in the rate of 
degradation of cytoplasmic ǃ-catenin and alteration of TCF-4 transcriptional activity and 
survivin expression leading to inhibition of apoptosis and promotion of mitosis (Boman and 
Huang 2008). 
Inactivation of the second APC allele occurs during the development of intestinal adenomas, 
and it has been proposed that the next critical event may be the movement of the progeny of 
the mutated stem cell moving from the niche into the proliferative zone of the crypt where 
they are freed from the constraints of the niche cells and are able to undergo further 
symmetric divisions and clonal expansion forming monocryptal adenomas (Humphries and 
Wright 2008). These are the earliest histologically detectable precursor lesions of tumor 
development and are thought to precede adenoma development. Further clonal expansion 
seems to be through crypt fission. Crypt fission is a normal process that leads to crypt 
replication. This process is responsible for the increased number of new crypts that arise 
during a short postnatal period, after which the total number of crypts increases only 
gradually with age. During crypt fission, development of a fissure bisects the crypt base and 
ascends longitudinally. This bifurcation results in the symmetric creation of two identical 
daughter crypts and must therefore be a process that results from symmetric ISC division. 
Experimental evidence suggests that mutant APC and an increasing rate of crypt fission, 
leads to abnormal, asymmetric crypt fissioning during adenoma development resulting in 
characteristic crypt branching and budding (Wasan et al. 1998). Crypt fission is also the 
mechanism that leads to the spread of mutant crypt populations in normal colonic 
epithelium. Further development of the lesion may be through random collision between 
neighboring neoplastic clones or through clonal interaction in which active cooperation 
between multiple initiated clones promotes continued survival and growth of the adenoma 
leading to genetic heterogeneity (Axelrod et al. 2006). Indeed, it has been shown that genetic 
alterations occur in the stroma from an early stage of carcinogenesis and that these may 
induce microregional differences in tumor susceptibility promoting loss of heterozygosity in 
the associated epithelium (Thliveris et al. 2005).  
5. Genetic differences between colon and rectal tumors 
The most well known model for colorectal carcinogenesis (the Vogelstein model) describes 
the progression of normal epithelium into adenomatous polyps and neoplasia and finally 
into metastatic carcinoma (Fearon and Vogelstein 1990). A series of specific genetic 
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alterations are responsible for the transition to more tumorigenic phenotypes. While 
alterations in the APC (adenomatous polyposis coli gene)/ǃ-catenin pathways as well as 
inactivation of mismatch repair proteins generally occur early, modifications to p53 and 
DCC/SMAD4/SMAD2 occur as one of the final steps in the progression to carcinoma. The 
step-wise progression of colorectal carcinogenesis through transitional dysplastic and 
adenoma stages is demonstrated by the high rate of success seen in preventing the 
development of colorectal cancer by removing polyps. Polyps represent the dysplastic and 
adenoma stages of colorectal carcinogenesis, and their removal prevents the development of 
carcinoma. 
There are three main pathways that lead to the genetic alterations responsible for colorectal 
tumorigenesis, the chromosomal instability (CIN) pathway, the mismatch repair (MMR) 
pathway and the hypermethylation phenotype. The CIN pathway is characterized by 
alteration of APC tumor suppressor gene signaling. A germline mutation of the APC gene 
results in the development of familial adenomatous polyposis (FAP) which is typified by 
hundreds to thousands of colorectal polyps by age 20-30. Tumors that developed via the 
CIN pathway have a high level of chromosomal instability that results in large numbers of 
deletions, insertions, and loss of heterozygosity. The MMR pathway to colorectal 
carcinogenesis results from a failure of DNA repair genes, in particular MLH1 and MSH2. 
This malfunction in DNA repair results in an accumulation of errors throughout the 
genome, particularly in areas called microsatellites. Microsatellites are short nucleotide 
regions that are repeated hundreds of times within the genome; thus, the MMR pathway is 
characterized by microsatellite instability. Germline mutations in one of the MMR  
genes results in hereditary nonpolyposis colorectal cancer (HNPCC). Finally, the 
hypermethylation pathway is characterized by a high incidence of methylation of CpG 
islands which may result in gene silencing of the MMR genes. 
In addition to these major pathways in colorectal carcinogenesis, there are specific genetic 
pathways that have a role in colorectal carcinogenesis. The gene K-ras is mutated in ~50% of 
sporadic colorectal cancer and in 50% of adenomas larger than 1 cm while rarely in smaller 
adenomas (Vogelstein et al. 1988). The lack of mutations in the smaller adenomas implies 
that the K-ras mutation is relevant to a later stage of progression. However, the presence of 
K-ras mutations in both nondysplastic aberrant crypt foci and hyperplastic polyps makes 
the role of these mutations unclear. 
Another commonly mutated gene in colorectal cancer is p53. In response to DNA damage 
and other stress, p53 induces responses ranging from cell cycle arrest and senescence to 
differentiation and is inactivated in 50-70% of colorectal cancers. The p53 gene is located on 
chromosome 17p which is lost in up to 75% of colorectal cancers, but it is lost rarely in 
adenomas. This suggests that the loss occurs late in the progression (Baker et al. 1990). 
One more common feature of colorectal cancers is the loss of chromosome 18q. The deletion 
is seen in 73% of sporadic colorectal cancers and 47% of large adenomas but less in smaller 
adenomas (Vogelstein et al. 1988). This divergence implies the chromosomal loss occurs 
later in tumorigenesis. Chromosome 18q contains three significant genes: DCC (“deleted in 
colon cancer”), SMAD4, and SMAD2. DCC functions as a tumor suppressor and has a role 
in cell-cell interactions. Loss of DCC expression is associated with a worse overall survival 
in colorectal cancer patients (Popat et al. 2007). As mentioned previously, SMAD4 and 
SMAD2 are both involved in BMP signaling as well as in the TGFǃ signaling cascade which 
modulates cell proliferation, apoptosis, and differentiation. 
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However, while cancers of the colon and rectum have generally been grouped into the 
single category of “colorectal” cancer, it has long been speculated that cancers that develop 
in different anatomical areas of the colon and rectum should be considered as separate 
diseases. Differences in the biology and function and risk factors between proximal colon, 
distal colon, and rectum may lend to these divergent disease entities. Genetic evidence also 
supports etiological evidence that colon and rectal tumors are different entities. These 
differences between colon and rectal tumors include incidence of certain gene mutations, 
change in gene expression, even differences in the mechanisms of carcinogenesis. The 
frequency of mutations to K-ras and APC differs between sites. Mutations to K-ras were 
more widespread in tumors of the colon. Rectal cancer more often has mutations restricted 
to APC while colon cancers often contain mutations in several genes (Frattini et al. 2004). In 
fact, the number of genetic mutations regardless of gene were higher in colon than the 
rectum (Li and Lai 2009). 
In addition to mutations, there are several genes that show different levels of expression 
between rectal and colon cancers including ǃ-catenin, MMR proteins, p53, and COX2 
(cyclooxygenase 2). ǃ-catenin binds the APC protein and is involved in regulating cell 
growth and adhesion between cells. The cellular localization of ǃ-catenin is altered between 
colon and rectal cancers. Nuclear ǃ-catenin expression was found more often in cancers of 
the rectum than colon (Kapiteijn et al. 2001), and reduced membranous and cytoplasmic 
staining was associated with increased metastatic disease in rectal cancer (Fernebro et al. 
2004). Unlike colon cancer, rectal tumors rarely show a loss of expression in MMR proteins 
including MLH1 and MSH2 (Fernebro et al. 2004). Over-expression of p53 was more 
common in rectal cancers than colon cancer; however, this may indicate a higher level of p53 
mutation in rectal cancer (Kapiteijn et al. 2001). In addition, 90% of rectal tumors 
demonstrate up-regulation of COX2 while only 20% of colon cancers had increased levels 
(Li and Lai 2009).  
 
 
Fig. 4. Gene expression linked cell survival and genome instability in rectal cancer. Genes 
identified in 4 gene expression studies of rectal cancer were highly represented by genes 
involved in cell survival and genome instability. Pathway generated by Ariadne Pathway Studio. 
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These differences in mutational and gene expression patterns demonstrate a fundamental 
difference in the carcinogenesis of rectal and colon cancer. With the low rate of MMR 
disruption seen in rectal cancer, the incidence of MSI is quite low. However, the incidence of 
CIN is high in rectal cancer as exemplified by the mutations seen in APC. The importance of 
genomic instability in rectal cancer is further illustrated by examining gene expression 
studies which were done to differentiate rectal cancer patients that respond to radiation 
therapy (Watanabe et al. 2006; Ojima et al. 2007; Rimkus et al. 2008) or patients that have 
local recurrence (Kalady et al. 2010). These four studies identify a total of 120 genes that are 
differentially expressed between rectal cancer patient populations. Of these genes, 30 are 
associated with cell survival, and 10 have been linked to genome instability (Figure 4). 
6. Current candidates as stem markers in rectal tumors 
Various cell surface markers (Table 1) have been used for the identification of cancer stem 
cells. These markers are used to isolate sub-populations of cells that are characterized by the 
ability to reconstitute the original tumor by xenotransplantation using a limited number of 
cells. Breast cancer stem cells that are CD44+ CD24-/low Lin- are able to form tumors in mice 
using as few as 100 cells while injection of tens of thousands of cells with different 
phenotypes fail to form tumors (Al-Hajj et al. 2003). Similarly, CD133+ cells from brain 
tumors are able to form tumors with an original xenograft of only 100 cells (Singh et al. 
2004). Even more astonishing, human ovarian cancer cells that have high ALDH activity and 
express the cell surface marker CD133 are able to form tumors in mice using as few as 11 
cells (Silva et al. 2011). 
 
Site Markers 
Brain / 
CNS 
CD133+ (Singh et al. 2004), ALDH1 activity (Wang et al. 2011) 
Breast CD44+ CD24-/low Lin- (Al-Hajj et al. 2003), ALD1 activity (Marcato et al. 2011) 
Esophagus Hoescht exclusion (Kalabis et al., 2008) 
HNSCC CD44+ (Harper et al. 2007), CD133+ (Yang et al. 2011), ALDH activity  
(Clay et al. 2010), Hoescht exclusion (Sun et al. 2010) 
Lung CD133+ (Bertolini et al. 2009), ALDH activity (Liang and Shi 2011) 
Melanoma CD20+ (Zabierowski and Herlyn 2008), CD133+ (Gazzaniga et al. 2010) 
Ovary ALDH activity (Silva et al. 2011), Hoescht exclusion (Hosonuma et al. 2011) 
Pancreas CD44+ CD24+ ESA+ (Lee et al. 2008), ALDH activity (Kim et al. 2011) 
Prostate CD44+ ǂ2ǃ1high CD133+ (Miki et al. 2007) 
Colon CD44+ ESAhigh (Dalerba et al. 2007), CD133+ (Ricci-Vitiani et al. 2010), CD166+ 
(Dalerba et al. 2007), ALDH activity (Huang et al. 2009), Lgr5+ve (Takahashi et 
al. 2011) 
Rectum CD44+ (Nagata et al. 2011), CD133+ (Nagata et al. 2011), CD133+ESA+ (Yang et 
al. 2010) 
Table 1. Stem cell markers. CNS: central nervous system; HNSCC: Head and neck squamous 
cell carcinoma; ALDH: aldehyde dehydrogenase-1; ESA: epithelial-specific antigen 
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As mentioned previously, there are several critical pathways that are involved in the 
maintenance of cancer stem cells including the Wnt, Sonic Hedgehog (SHH), Notch, 
phosphoinosital-3-kinase (PI3K), and bone morphogenic protein (BMP) pathways (Brabletz 
et al. 2009). Interestingly, most of the known cancer stem cell markers are not directly 
related to these pathways; however, these signaling pathways are up-regulated in these 
cancer stem cell-enriched sub-populations. Pancreatic cancer stem cells that are CD44+ 
CD24+ ESA+ show an up-regulation of SHH and BMI-1 signaling. These pancreatic cancer 
stem cells represent less than 1% of all pancreatic cancer cells (Lee et al. 2008), and 100 of 
these pancreatic stem cells are able to form tumors that are indistinguishable from the 
original tumor (Chen et al. 2011). 
In colorectal cancer, ALDH+ cells are rare in the normal colorectal epithelium and located 
exclusively in the normal crypt base which is the proposed location for colorectal stem cells. 
As colorectal carcinogenesis progresses from normal through adenoma and carcinoma, the 
number of ALDH+ cells increases as well as being distributed more extensively (Huang et 
al. 2009). Colorectal tumor cells that express both CD44 and ESA are able produce tumors 
and reproduce the full heterogeneity of the original tissue. CD133+ colorectal cancer stem 
cells constitute 2.5% of all cells in the tumor (Ricci-Vitiani et al. 2010). These CD133+ cells are 
able to reproduce the original tumor while the CD133- cells cannot form tumors. However, it 
is worth noting that a study using fractionating dilution revealed that 1 in 262 CD133+ cells 
are able to form tumors (O'Brien et al. 2007). While significantly enriched compared to the 
unfractionated cell population which form tumors at a rate of 1 in 57,000, it still illustrates 
that not all CD133+ cells are able to reconstitute the original tumors. 
Although CSCs have been studied in colon cancer, the existence and implication of stem 
cells has not been extensively studied in rectal cancer. In a case study, Yang et. al. found 
elevated levels of CD133+ ESA+ cancer stem cells circulating in the blood of a 75-year old 
rectal cancer patient who later developed liver metastasis (Yang et al. 2010). 
Immunohistological analysis of rectal cancer tissue demonstrated that local recurrence was 
greater for patients that were positive for either CD133 or CD44 (Nagata et al. 2011). Yasuda 
and colleagues (Yasuda et al. 2009) showed that elevated CD133, but not VEGF or EGFR, 
was a predictive marker of distant recurrence after preoperative chemoradiotherapy in 
rectal cancer while Wang et. al. (Wang et al. 2009) showed that the proportion of CD133+ 
cells was a significant prognostic factor for adverse disease-free survival and overall 
survival independent of TNM stage, tumour differentiation or lymphovascular invasion. 
More recently, Kojima and colleagues (Kojima et al. 2010) studied 92 cases of rectal cancer of 
which 43 patients received preoperative chemoradiation therapy and 49 patients underwent 
surgery alone. Forty pretreatment biopsy specimens from 43 patients in the preoperative 
chemoradiation therapy group were also analyzed. CD133-positive cases were more 
common in the preoperative chemoradiation therapy group than in the surgery-alone 
group. Furthermore, CD133-positive cases were more common in the preoperative 
chemoradiation therapy group than in pretreatment biopsy specimens. In the preoperative 
chemoradiation therapy group, the CD133-positive cases showed poorer prognosis than the 
CD133-negative cases. These studies suggest that the CD133+ population is important for 
outcome and that chemoradiation enriches this population.  
The biological function of CD133 remains unknown. It is a transmembrane pentaspan 
protein that was initially described as a surface antigen which was specific to human 
hematopoietic stem cells (Yin et al. 1997). Utilizing the literature mining software found in 
Ariadne Pathway Studio, Figure 5 illustrates the known relationships found between CD133 
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and other genes and cellular processes. Cellular processes that are associated with CD133 
include those that are expected to be involved with cancer stem cells: cell death, 
morphogenesis, apoptosis, cell differentiation, cell proliferation, and drug response 
(response to drug). Others may provide hints at important processes that have yet to be 
investigated: lipid metabolism, glucose metabolism, and vascularization. In addition, CD133 
is linked with well-known cancer-related genes such as p53, Myc, Src, and transforming 
growth factor ǃ1 and the TGFǃ-associated SMAD6 and SMAD7. Expression of the gene HIF-
1ǂ in conjunction with CD133 is associated with tumor recurrence following chemoradiation 
(Saigusa et al. 2011). Also associated with recurrence of rectal cancer after  chemoradiation is 
putative stem cell marker POU class 5 homeobox 1 (POU5F1). Expression of CD133, 
POU5F1, and the SOX2 gene following treatment was associated with poor disease-free 
survival. 
The addition of other known cancer stem cell markers such as CD44 and ESA (EPCAM) to 
the diagram exemplifies the level of similarity in signaling. Figure 5 shows CD133 
associated with 61 other genes and cellular processes. While ESA is associated with 10 of 
these entities, CD44 has been linked with almost half. CD44 has been associated with the 
inhibition of apoptosis, cell differentiation, and p53 signaling/expression. Both CD133 and 
CD44 are linked to CXCL12 (chemokine (C-X-C motif) ligand 12). CXCL12 and its receptor 
CXCR4 have previously been associated with the mobilization and homing of hematopoetic 
stem cells (Juarez and Bendall 2004). Interestingly, CXCR4 overlaps much of the CD133 
signaling and has been implicated in cancer stem cell signaling at several other sites. 
Sustained CXCR4/CXCL12 signaling occurs in prostate cancer stem cells (Mimeault and 
Batra 2011) and is involved in the up-regulation of stem cell-related gene expression in 
breast cancer cells (Zhang et al. 2011). Additionally, CXCR4 was identified as a therapeutic 
target of glioblastoma stem cell-like cell lines (Schulte et al. 2011). This implies that, while 
many markers may be used to identify cancer stem cells, much of the signaling behind these 
superficial membrane markers may be quite similar. 
7. Stem cells and treatment response 
The mainline cancer therapies of conventional chemo- and radiotherapy target rapidly 
cycling cancer cells and can cause impressive, but usually temporary, clinical remissions. 
This initial remission followed by local recurrence would support the argument for the 
existence of a small subpopulation of resistant CSCs, while at the same time the majority of 
the non-CSCs being responsive to the treatment. Treatment failure could be explained by 
several CSC characteristics that would make them difficult to eradicate by conventional 
agents. First, they may be slow-cycling or quiescent rendering them less sensitive to agents 
that target actively cycling cells. Second, a characteristic of many normal stem cells is the 
increased activity of ABC transporter proteins as a protective mechanism against 
environmental toxins; these are also up-regulated in CSCs (Dean et al. 2005). Third, there are 
data suggesting that CSCs may be more resistant to radiation (Bao et al. 2006) although this 
has not been universally found (McCord et al. 2009). 
CD133 has been extensively studied in the context of radiation sensitivity in the setting of 
glioma. An increase of the CD133+ fraction following irradiation of human glioma cells has 
been shown in vitro as well as in tumors in nude mice (Bao et al. 2006). The CD133+ cell 
fraction was found to have a reduced sensitivity to radiation-induced apoptosis. 
Interestingly, when CD133+ cells were irradiated with 3Gy, they were able to initiate tumors  
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Fig. 5. Genes and cellular processes associated with CD133 expression. The literature mining 
software in Ariadne Pathway Studio software identifies genes and cellular processes that 
have been shown to be associated with CD133. This figure was supplemented by adding the 
stem cell markers CD44, ESA (EPCAM), and CXCR4.  
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with almost the same efficacy than the non-irradiated CD133+ cells. A clinical study in 
atypical teratoid/rhabdoid tumors demonstrated a correlation of the amount of 
immunohistochemically detected CD133+ cells with resistance to combined chemoradiation 
and decreased survival (Chiou et al. 2008). These data are supported by evaluations of 
glioma (Murat et al. 2008) and rectal cancer patients (Wang et al. 2009). All these studies 
show correlations between CD133 expression and efficacy of radiotherapy or combined 
treatment. Similarly, studies have also shown that CD133 positivity is associated with 
chemoresistance in glioma (Nakai et al. 2009), oral squamous cancer (Zhang et al.), and 
mesothelioma (Cortes-Dericks et al. 2010) amongst others. A large clinical study of 501 cases 
of human colorectal cancers showed that CD133-overexpressing tumors were more resistant 
to 5-FU–based chemotherapy and that CD133 expression was associated with poor 
prognosis (Ong et al. 2010). A recent study showed that treatment of human HT-29 
colorectal cancer cells with high doses of 5-FU or oxaliplatin resulted in enrichment of 
CD133+ and CD44+ CSCs, which also exhibited decreased in vitro proliferation rate (Dallas 
et al. 2009). Interestingly in another colorectal cell line study, a recent publication has 
suggested that although CD133+ cells had higher in vivo tumor-forming ability than CD133− 
cells, it was the CD133− cells that were more resistant to 5-fluorouracil (FU) treatment 
(Hongo et al. 2011).  
Although newer targeted agents such as cetuximab and bevacizumab are being tested in 
both frontline (Minsky et al. 2010) therapy and the metastatic setting (Cunningham et al. 
2004; Hurwitz et al. 2004), they have modest effects on disease-free survival and overall 
survival. It would seem that the current combined modality therapies for rectal cancer will 
not be effective against CSCs no matter what combination is used. However, the most 
effective method to target CSCs has yet to be elucidated, but a number of possibilities exist 
including the administration of differentiating agents such as salinomycin (Gupta et al. 
2009), targeting the specific signaling pathways of the CSCs (hedgehog, wnt, Notch) with 
drugs like cyclopamine (Merchant and Matsui 2010; Pannuti et al. 2010; Takahashi-Yanaga 
and Kahn 2010), targeting the microenvironmental niche of CSCs (LaBarge 2010), targeting 
the DNA checkpoint response (Frosina 2009), or using normal stem cells to home to the 
region of tumor (Hu et al. 2010). It is likely that future therapies will include inhibitors of 
survival pathways, along with immune cells, differentiation agents, and cytotoxic drugs, as 
a combination. 
Immunological approaches have been demonstrated to be effective against CSCs in 
colorectal cancer. It has been shown that inhibiting the IL-4 signaling transduction pathway 
with an anti–IL-4 neutralizing antibody or an IL-4 receptor ǂ antagonist sensitized CSCs to 
chemotherapeutics through down-regulation of anti-apoptotic proteins, such as cFLIP, Bcl-
xL, and PED (Todaro et al. 2007). The same group has also shown that incubation of colon 
CSCs with the bisphosphonate zoledronate induced an efficient Ǆǅ T-cell response. These 
immune cells have been shown to be effective at killing different tumor cells in vitro, but 
this was the first report of using Ǆǅ T-cell to target CSCs (Todaro et al. 2009).  
Another important area of future investigation will be to determine the optimal timing of 
CSC-targeted therapies with other modalities, i.e. should it be co-administration of agents 
for newly diagnosed tumor or sequential scheduling after a remission to standard treatment 
has been obtained or at the time of progression after a standard treatment (Al-Hajj et al. 
2004). A crucial element in optimizing timing will be the development of novel imaging 
probes to develop strategies for robust and efficient tracking and validation of CSCs and 
their niche under in vivo conditions. This will pave the way to better elucidate the 
www.intechopen.com
 Colorectal Cancer – From Prevention to Patient Care 
 
316 
underlying regulatory mechanisms of CSC and develop platforms for targeted 
theragnostics. 
8. Conclusions 
The CSC model, if generally correct, has important implications for the current paradigm of 
treatment for rectal cancer. The practice of small, successive improvements in survival by 
the refinement of current schedules and addition of newer agents is unlikely to result in 
significant advances in treatment outcomes. Gene expression analyses of CSCs populations 
have the possibility to identify novel diagnostic markers and novel therapeutic targets. A 
recent study identified EGR1 to the be the most highly expressed gene in CD133 positive 
colorectal cancer cells (Ernst et al. 2011). EGR1 is known to regulate Wnt through up-
regulation of TCF4, which induces stem cell marker LGR5. Previous studies identified 100 
candidate-genes, which were differentially expressed in the CD133 positive fraction 
(Regenbrecht et al. 2008) of which 10 genes were shown to be differentially regulated 
between the different studies. However, 9 of these 10 genes were shown to form an 
interactive network with each other and that these genes were positioned at the interface 
between proliferative pathways (JAK/STAT) and differentiating pathways (HOX, PBX, 
MEIS, GATA2). Of importance in this cascade was the gene KIT which encodes the receptor 
for stem cell factor (SCF). It is clear from Figure 5 that CD133 is involved in many signaling 
pathways and identifying the candidate pathways for future drug development will be 
challenging. Equally challenging will be targeting pathways of stem cell self renewal 
without affecting this crucial process in normal stem cells. Thus, the elucidation of the 
mechanisms regulating the survival, self-renewal, and differentiation of normal and CSCs 
could potentially lead to significant advances in the treatment of neoplastic diseases 
including rectal cancer. 
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world remain unfavorable. When we consider the substantial morbidity and mortality that accompanies the
disease, the acute need for improvements and better solutions in patient care becomes evident. This volume,
organized in five sections, represents a synopsis of the significant efforts from scientists, clinicians and
investigators towards finding improvements in different patient care aspects including nutrition, diagnostic
approaches, treatment strategies with the addition of some novel therapeutic approaches, and prevention. For
scientists involved in investigations that explore fundamental cellular events in colorectal cancer, this volume
provides a framework for translational integration of cell biological and clinical information. Clinicians as well as
other healthcare professionals involved in patient management for colorectal cancer will find this volume
useful.
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